Hypokalaemic periodic paralysis (hypoPP) is an auto-CACNL1A3 gene and five to the SCN4A gene. One mutation has not been described before. Some somal dominant muscle disorder characterized by episodic attacks of muscle weakness associated with a remarkable clinical features were observed in a large hypoPP family carrying an SCN4A mutation: a complete decrease in blood potassium levels. Mutations in the gene encoding the skeletal muscle voltage-gated calcium penetrance in men and women, an early age at onset, postcritic myalgias and an increased number and channel α-1 subunit (CACNL1A3) account for the majority of cases. Recently, mutations in the gene severity of attacks induced by acetazolamide. A muscle biopsy, performed in two members of this family, coding for the skeletal muscle voltage-gated sodium channel α subunit (SCN4A) have been reported in a revealed a peculiar myopathy characterized by tubular aggregates. In contrast, vacuoles were predominant in small number of hypoPP families. In order to determine the relative frequency of the CANCL1A3 and SCN4A muscles from hypoPP patients carrying CACNL1A3 mutations. Our findings point to the usefulness of a mutations in a large population of hypoPP patients, and to specify the clinical and pathological features molecular characterization of hypoPP patients in clinical practice. They also provide new clues for understanding associated with each of them, we searched for mutations in 58 independent hypoPP index cases. We detected the the mechanisms behind functional and structural alterations of the skeletal muscle in hypoPP. causative mutation in 45 cases: 40 were linked to the Keywords: hypokalaemic periodic paralysis; calcium channel; sodium channel; tubular aggregates Abbreviations: CACNL1A3 ϭ α-1 subunit of adult skeletal muscle voltage-dependent calcium channel; hypoPP ϭ hypokalaemic periodic paralysis; hypoPP-1 ϭ hypoPP linked to CACNL1A3; hypoPP-2 ϭ hypoPP linked to SCN4A; PCR ϭ polymerase chain reaction; RFLP ϭ restriction fragment length polymorphism; SCN4A ϭ α subunit of adult skeletal muscle voltage-dependent sodium channel; SSCA ϭ single strand conformation analysis.
Introduction
Hypokalaemic periodic paralysis (hypoPP) is an autosomal intense in women, who may experience only a small number of attacks. Provocative factors include carbohydrate-rich dominant muscle disorder characterized by episodic attacks of muscle weakness accompanied by a decrease in blood meals, rest after exercise, sudden exposure to heat or cold, glucose perfusion and acute stress. A progressive muscle potassium levels. The age at onset of recurrent attacks is usually within the first or second decade. Attacks become weakness may also develop, independently of the number of attacks, starting in most cases after 40 years of age. rarer or disappear after 40 years of age. The frequency of attacks varies from patient to patient, even within the same Histopathological studies, performed before the discovery of the genes involved in hypoPP, have shown myopathic family. The expression of the phenotype is usually less alterations characterized by the presence of vacuoles or European Union and French bioethics laws and the Declaration of Helsinki. DNA was extracted from blood tubular aggregates in the muscle fibres (Bekeny, 1961; Engel et al., 1970) .
samples by a classical phenol-chloroform protocol or a rapid procedure using Qiagen DNA minikit (Qiagen S.A., Les The majority of hypoPP families previously were linked to hypoPP-1 on chromosome 1q32 (Fontaine et al., 1994) .
Ulis, France). The pedigree of Family 41 is shown in Fig. 1 . In this large Subsequent gene sequencing demonstrated that mutations in the gene encoding the α-1 subunit of the skeletal muscle French family, linkage analysis had already excluded the hypoPP-1/CACNL1A3 locus (Plassart et al., 1994a) . The calcium channel (CACNL1A3) caused hypoPP-1 (JurkatRott et al., 1994; Ptacek et al., 1994a) . This α-1 subunit is proband was a 43-year-old man. Paralytic attacks began at age 10 years (one/month) and their frequency and duration composed of four homologous domains (DI-DIV), each of them made of six transmembrane segments (S1-S6) increased between ages 13 and 25 years (three/week, lasting 12-24 h, with postcritic myalgias lasting several days). A (Catterall, 1996; Lehmann-Horn and Jurkat-Rott, 1999) . Three point mutations affecting an arginine have been found percritic hypokalaemia was demonstrated (the lowest was 1.4 mmol/l). Attacks occurred frequently in the morning and in segment S4 of domains II and IV (R528H, R1239H and R1239G) (Jurkat-Rott et al., 1994; Ptacek et al., 1994a) . The treatment by potassium chloride salts decreased the frequency of attacks by two-thirds. Triggering factors included R528H and R1239H mutations are responsible for most cases of hypoPP-1 and their relative incidence varies from one carbohydrate-rich meals, sudden rest after exercise, sudden exposure to heat or cold and general anaesthesia. Treatment population to another (Elbaz et al., 1995; Fouad et al., 1997; Sillen et al., 1997 ). An incomplete penetrance in women and by acetazolamide was attempted at age 36 years but was interrupted because of the occurrence of subintrant attacks a later onset were observed for the R528H mutation (Elbaz et al., 1995; Fouad et al., 1997) . Although the majority of of paralysis with intercritic weakness during several weeks. At age 40 years, a permanent muscle weakness affecting the hypoPP families were linked to the hypoPP-1 gene, at least one large family was not, suggesting the existence of a upper segments of the lower and upper limbs was evidenced. A muscle biopsy was performed at age 42 years. His second hypoPP locus (hypoPP-2) (Plassart et al., 1994a) . Furthermore, an extensive search for CACNL1A3 mutations 18-year-old son experienced the first paralytic attacks at age 10 years. The frequency and duration of these attacks in large samples of hypoPP families did not disclose mutations for a number of them (Fouad et al., 1997) . Recently, linkage developed in a manner similar to that described for his father. At age 17 years, no permanent muscle weakness analysis, gene sequencing and in vitro expression studies demonstrated that the gene encoding the α subunit of the was evidenced on clinical examination although the patient complained of muscle fatigue. Acetazolamide had the same skeletal muscle sodium channel (SCN4A) located on chromosome 17q22-23 was the second locus hypoPP-2 deleterious effect as for his father. A muscle biopsy was performed at age 17 years. Clinical information about the (Bulman et al., 1999; Jurkat-Rott et al., 2000) .
In the present work, we screened 58 hypoPP families for proband, his son and nine other affected relatives is summarized in Table 1 and Fig. 1 . all known mutations in CACNL1A3 and SCN4A genes that were associated with this disease. CACNL1A3 mutations were found in 40 families and SCN4A mutations in five families. We also identified a new hypoPP mutation in the
Methods for mutation screening
Mutations in the CACNL1A3 and SCN4A genes were searched SCN4A gene.
for in all proband DNAs. The CACNL1A3 R528H mutation resulting from a G → A transition at nucleotide 1583 was searched for by performing a polymerase chain reaction
Material and methods
(PCR) and analysing the restriction fragment length polymorphisms (RFLPs) of the PCR products. Primers and
Patients
The search for a causal mutation was undertaken in 58 restriction endonuclease were as described (Jurkat-Rott et al., 1994) . PCR was performed in 25 µl of standard PCR buffer independent probands with a diagnosis of hypoPP. Probands presented episodes of flaccid paralysis with a low percritic containing 1.5 mM MgCl 2 , 0.2 mM of each dNTP, 240 µM of each primer, 0.025 U/µl of Taq polymerase Gold (Appliedpotassium level (blood potassium level Ͻ3.5 mmol/l during the attacks). Myotonia was neither clinically present nor Biosystems, Foster City, Calif., USA) and 80 ng of DNA.
Steps of amplification were 94°C 15 min (94°C 30 s, T°a n detectable by electromyography. Forty-four patients were index cases in families with several affected members, 30 s, 72°C 1 min) ϫ 40 cycles, 72°C 3 min. T°a n decreased from 60 to 50°C by 1°steps in the first 10 cycles and compatible with an autosomal dominant mode of inheritance. Fourteen cases were apparently sporadic. Secondary causes remained at 50°C for the last 30 cycles. A 5 µl aliquot of each 77 bp PCR product was mixed with 2 IU of BbvI, 1.7 µl of hypoPP were excluded, especially in sporadic cases. Clinical data for probands and related mutation carriers are of appropriate 10ϫ buffer and 10 µl of H 2 O. Mixes were left under mineral oil at 37°C for 5 h. The resulting digestion summarized in Table 1 . Blood samples were obtained after the informed consent of each individual according to the products were electrophoresed for 1 h on a 4% agarose gel 14 Ϯ 3.1 (n ϭ 23) 9.6 Ϯ 4.7 (n ϭ 18) 9.6 Ϯ 2.9(n ϭ 11) M: 14.5 Ϯ 1.5 (n ϭ 19) M: 10.4 Ϯ 4.8 (n ϭ 9) M: 9 Ϯ 3 (n ϭ 6) F: 11.8 Ϯ 7.1 (n ϭ 4) F: 8.8 Ϯ 4.8 (n ϭ 9) F: 10.2 Ϯ 3.1 (n ϭ 5) Percritic [1% standard agarose, 3% Nusieve (Bio Whittaker Molecular A 5 µl aliquot was electrophoresed on a 10% polyacrylamide gel at 25°C for 4 h. The gel was then fixed, silver-stained Applications, Rockland, USA), 0.5ϫ TBE, 0.5 µg/µl ethidium bromide], in a 0.5ϫ TBE buffer at 100 V. Bands were and dried. Mutations were searched for in exon 12 of SCN4A by visualized by ultraviolet transillumination.
Mutations of CACNL1A3 exon 30 (R1239H and R1239G) PCR-SSCA (Jurkat-Rott et al., 2000) . Primers were 5Ј-CTCTGTGACAGGGCCTCATG-3Ј (F) and 5Ј-TCCTCwere searched for by performing a PCR and analysing the PCR products by means of single strand conformation ACCCCACCCCCATCC-3Ј (R) (250 bp). PCR was performed in 25 µl of standard PCR buffer containing 2 mM analysis (SSCA) (Ptacek et al., 1994a) . Primers were 5Ј-ATGAGAGTGCCCGCATCTCC-3Ј (F) and 5Ј-CTGTMgCl 2 , 0.2 mM of each dNTP, 240 µM of each primer, 0.025 U/µl of Taq polymerase Gold and 80 ng of DNA. TGCACCTGGAAGGACTTG-3Ј (R) (181 bp). PCR was performed in 25 µl of standard PCR buffer containing 1.5 mM
Steps of amplification were 94°C 15 min (94°C 30 s, 61°C 30 s, 72°C 1 min) ϫ 35 cycles, 72°C 3 min. PCR products MgCl 2 , 0.2 mM of each dNTP, 240 µM of each primer, 0.025 U/µl of standard Taq polymerase (Applied-Biosystems, Foster were denatured in two different conditions. In the first, 3 µl of each PCR were mixed with 20 µl of S medium. In the City, Calif., USA) and 80 ng of DNA. Steps of amplification of the 181 bp product were 94°C 5 min (94°C 30 s, T°a n second, 4 µl of each PCR were mixed with 8 µl of 100% formamide, 10 mM EDTA, 0.05% bromophenol blue and 30 s, 72°C 1 min) ϫ 40 cycles, 72°C 3 min. T°a n decreased from 70 to 58°C by 1.2°steps in the first 10 cycles and 0.05% xylene cyanol (FE medium). Both kinds of mixes were denatured for 5 min at 98°C, kept on ice, and 5 µl of remained at 58°C for the last 30 cycles. A 3 µl aliquot of each PCR was mixed with 20 µl of 10% saccharose, 0.05% each were electrophoresed at two different temperatures (7 and 25°C) on 10% polyacrylamide gels. Gels were then bromophenol blue and xylene 0.05% cyanol (S medium). The mix was denatured for 5 min at 98°C and kept on ice.
fixed, silver-stained and dried.
Muscle biopsy and histopathological examination
Open deltoid muscle biopsies were performed under local anaesthaesia. Specimens were frozen and sectioned at a 10 µm thickness. The following histochemical reactions were carried out: haematoxylin-eosin, modified Gomori's trichrome, oil-red O, NADH (nicotinamide adenine dinucleotide)-tetrazolium reductase, periodic acid-Schiff, myophosphorylase, myofibrillar adenosine triphosphatase (pH 4.3, 4.6 and 9.4), succinate dehydrogenase and cytochrome c oxidase. Others specimens were paraffinembedded, serially sectioned and examined by haematoxylineosin and Congo red stains.
Results

Calcium (CACNL1A3) and sodium (SCN4A) channel gene mutations in hypoPP
The presence of a CACNL1A3 (hypoPP-1) R528H mutation was suggested by a PCR digestion assay which showed a partial loss of the BbvI restriction site in 26 probands (families 1-26). In all cases, direct sequencing confirmed a heterozygous G → A transition at nucleotide 1583, resulting in a R528H mutation (Fig. 2) . A R528H mutation was also demonstrated in 60 relatives (34 men and 26 women). Fourteen probands (Families 27-40) showed an additional band at CACNL1A3 exon 30 by SSCA analysis, suggesting a R1239H mutation (hypoPP-1). Direct sequencing revealed a heterozygous G → A transition at nucleotide 3716 resulting in a R1239H mutation (Fig. 2) . The occurrence of a R1239H mutation was also demonstrated in 22 relatives (nine men and 13 women).
The SSCA screening of SCN4A (hypoPP-2) exon 12 in probands was performed for each PCR sample in four different conditions by combining two different denaturing media (S and FE) and two temperatures of electrophoresis. substitution at position 672, respectively (Figs 1 and 2 ). All polyacrylamide gel at 25°C. Gels were fixed and silver stained.
were in a heterozygous state. The R672G mutation was searched for in 16 affected (eight men and eight women) and 13 adult unaffected relatives (nine men and four women) Direct sequencing was used to sequence variants responsible for each abnormal RFLP or SSCA profile using of the Family 41 proband. This mutation was found in all affected and in none of the unaffected relatives. The R672H a fluorescent procedure and a DNA sequencer according to the manufacturer protocol (ABI 377; Applied-Biosystems, mutation was found in Family 44 proband's father who had only one paralysis attack at age 30 years. Samples from Foster City, Calif., USA). relatives of Families 42, 43 (R672H mutation) and 45 (R672S nearest 1 year), respectively ( Table 1 ). The observed mutation) were not available. The SCN4A R672S mutation differences between R528H and R1239H populations, as well had not been reported before the present study. We confirmed as between R528H and R672G populations were statistically its absence in 50 unrelated normal individuals, i.e. 100 significant (U test, P ϭ 0.003 and P ϭ 0.0012, respectively). chromosomes (data not shown).
Episodes of myalgias were reported for five R528H, two R1239H and 10 R672G patients (Table 1) . They were percritic in four out of five R528H and in both R1239H patients, but
Clinical phenotypes associated with CACNL1A3
were postcritic in the remaining R528H and in all R672G patients for whom myalgias could last from one to (hypoPP-1) and SCN4A (hypoPP-2) mutations several days. A prophylactic acetazolamide treatment was The screening for hypoPP-1 and hypoPP-2 mutations in a administered to eight R528H, 13 R1239H and three R672G population of 58 hypoPP probands yielded the following patients (Table 1 , Fig. 1 ). This treatment was beneficial in distribution: 26 cases (45%) carrying CACNL1A3 R528H five out of eight R528H and eight out of 13 R1239H patients, (23 familial, three sporadic), 14 cases (24%) carrying ineffective in three out of eight R528H and four out of 13 CACNL1A3 R1239H (10 familial, four sporadic), three cases R1239H patients, and deleterious in one R1239H patient and (5%) with SCN4A R672H (two familial, one sporadic), one all three R672G patients. case (2%) with SCN4A R672G (familial) and also one (2%)
The development of a progressive myopathy was observed with SCN4A R672S (familial). No mutation was found in in four male and four female R528H carriers (Table 1) . 13 index cases (22%).
All affected men and one affected woman had previously The penetrance of the R672G mutation was complete since experienced paralytic attacks, whereas three affected women all mutation carriers, both men and women, presented with from the same family never had attacks. A permanent muscle repetitive paralysis attacks (Table 1 ). In contrast, six adult weakness was observed in three men and four women with R528H female carriers and one adult male carrier never the R1239H mutation (Table 1 ). All affected R1239H carriers experienced paralytic attacks. Three adult R1239H female experienced recurrent paralytic attacks except one woman carriers had only a single attack which was triggered by an who experienced a single attack at age 34 years and later acute stress (influenza, surgery or intoxication). The mean developed a progressive myopathy in her seventies. A ages at onset of hypoPP for R528H, R1239H and R672G progressive myopathy was observed in three male and two mutations were 14 Ϯ 3 years (n ϭ 22), 10 Ϯ 5 years (n ϭ 18) and 10 Ϯ 3 years (n ϭ 11) (data corrected to female R672G carriers of Family 41 (Table 1) .
preparations. Succinate dehydrogenase histochemical reaction showed no mitochondrial proliferation and there was no cytochrome c oxidase-deficient fibre. This pattern corresponded to tubular aggregates. The finding of a tubular aggregate myopathy in two R672G individuals contrasted with the vacuolar myopathy observed in patients carrying the R528H mutation (two women from the same family and the proband from another family). Published cases on the histological changes observed in muscle biopsies of hypoPP patients are summarized in Table 2 .
Discussion
Although mutations in the voltage-gated calcium channel (CACNL1A3) remain the major causes of hypoPP (i.e. hypoPP-1), we clearly confirm in the present study that mutations at amino acid 672 of the sodium channel (SCN4A) also cause hypoPP (i.e. hypoPP-2). The screening of a large population of 58 independent patients yielded 69% (40 families) of hypoPP-1 and 9% (five families) of hypoPP-2 cases.
The evidence of hypoPP2-related mutations of SCN4A expands the spectrum of diseases due to mutations in this gene. To date, Ͼ20 SCN4A mutations have been identified in normo-or hyperkalaemic periodic paralysis (Ptacek et al., 1991 (Ptacek et al., , 1994b Rojas et al., 1991; Plassart et al., 1994b) , (Ptacek et al., 1993 (Ptacek et al., , 1994b ; Plassart biopsies of two patients with hypoPP2-associated myopathy.
et al., 1994b, 1996) , potassium-aggravated myotonia (Heine S4 segment of domain IV, similarly to the mutations in the S4 region of domain II causing hypoPP-2. These paramyotoniaHistopathological characterization of hypoPPassociated mutations uncouple inactivation from activation, which is not the case for hypoPP-2 mutations (Chahine et al., 
associated myopathy
Histological analysis was performed on muscle biopsies from 1994; Jurkat-Rott et al., 2000) . This confirms that DIIS4 and DIVS4 segments have different functions in the gating of hypoPP-2 Family 41 proband and his son. Both patients showed the same pathological changes, though in a more the sodium channel α-subunit, as previously demonstrated by in vitro mutagenesis studies. It also provides some clues severe form for the father (Fig. 3) . There was a slight abnormal variability in fibre size, with some isolated atrophic for understanding why mutations which affect a similar amino acid in different S4 segments lead to distinct fibres. The distribution of the fibre types was normal and the number of central nuclei remained in the normal range. There phenotypes (Kontis and Goldin, 1997; Kontis et al., 1997) . HypoPP due to the SCN4A R672G mutation might be were no inflammatory cell exudates, basophilic regenerating fibres, necrotic fibres or vacuoles. Phosphorylase activity was associated with peculiar clinical features. The age at onset for SCN4A R672G carriers differs significantly from that normal. The striking abnormality consisted of multifocal accumulations of a well-demarcated material in type 2 observed in CACNL1A3 R528H carriers, but is reminiscent of that reported for the patients carrying the CACNL1A3 fibres. These subsarcolemmal areas stained markedly with the NADH-tetrazolium reductase and were present in 25 and R1239H mutation. The complete penetrance of the disease at age 20 years in Family 41 stands in contrast to the 12% of type 2 fibres in father and son, respectively (Fig. 3) . These aggregates were slightly basophilic in haematoxylinincomplete penetrance at the same age displayed by CACNL1A3 R528H and R1239H families. Postcritic eosin, red in Gomori's trichrome, darkly reactive in NADHtetrazolium reductase, normal in succinate dehydrogenase myalgias and cramps were reported by the proband and nine other affected relatives in Family 41, whereas only one and unreactive in periodic acid-Schiff and in myosin ATPase Table 2 Muscle histological abnormalities reported in hypokalaemic periodic paralysis M ϭ male; F ϭ female; pa ϭ age (years) at onset of paralysis attacks; pmw ϭ age (years) at reported permanent muscle weakness; vac ϭvacuoles; ta ϭ tubular aggregates; nsp ϭ non-specific myopathic changes; nl ϭ normal aspect; mito ϭ mitochondrial changes; nf ϭ not found; nd ϭ not searched for. *The mutation was determined after histological findings were published. CACNL1A3 R528H and no R1239H patient complained of R528H mutation in whom a muscle biopsy was performed, as well as in at least six other reported R528H patients this symptom. Acetazolamide is a carbonic anhydrase inhibitor, which has been shown to decrease the number of (Tables 1 and 2 ), a pure vacuolar myopathy was observed with no tubular aggregates. In contrast, a major tubular attacks in hypoPP patients (Griggs et al., 1970; Vroom et al., 1975; Johnsen, 1977; Goulon et al., 1978) . However, sporadic aggregate myopathy exclusive to type II fibres, with no vacuoles, was observed in two patients with the SCN4A hypoPP cases were reported in which acetazolamide precipitated muscle weakness (Torres et al., 1981; Vern et al., R672G mutation. The greater severity of the lesions observed in the father and the specific involvement of type II fibres 1987). In one of these cases, a tubular aggregate myopathy was found, similar to that observed for patients of Family may suggest that the extent of tubular aggregates increases with age and is related to exercise. Tubular aggregates consist 41. Treatment by acetazolamide increased the frequency and the severity of attacks in the three tested patients of Family of densely packed double-walled tubules originating from the terminal cisterns of the sarcoplasmic reticulum (Engel 41, and only in one out of the 13 acetazolamide-treated CACNL1A3 R1239H patients. No deleterious effect of this et al., 1970; van Engelen and Ter Laak, 1999) . They are found as a minor feature in skeletal muscle of normal patients treatment was observed in any of eight CACNL1A3 R528H patients. We therefore suggest that hypoPP patients with but also in subacute alcoholic myopathy, drug myopathy, malignant hyperthermia and metabolic or inflammatory sodium channel mutations might not benefit from acetazolamide treatment, and that genetic testing in hypoPP myopathies (Morgan-Hughes, 1998 ). Tubular aggregates are major features of some inherited or sporadic disorders such should be undertaken before starting the treatment.
The hypoPP-associated myopathy caused by the SCN4A as the familial limb-girdle myasthenia or weakness, the exercise-related muscle pain and cramp syndrome and the R672G mutation might have distinctive histopathological characteristics. In the three patients with the CACNL1A3 gyrate atrophy of the choroid and retina (Morgan-Hughes, using both light and electronic microscopy (Vern et al., 1987; Gold and Reichmann, 1992; Fouad et al., 1997 no clinical permanent muscle weakness (Bekeny, 1961;  Catterall WA. Molecular properties of sodium and calcium channels. Howes et al., 1966; Odor et al., 1967 ; Buruma and Bots, [Review] . J Bioenerg Biomembr 1996; 28: 219-30. 1978; Gerard et al., 1978) . In some hypoPP cases, tubular aggregates could also be detected among predominant Chahine M, George AL Jr, Zhou M, Ji S, Sun W, Barchi RL, et al.
vacuoles using electronic microscopy (Odor et al., 1967;  Sodium channel mutations in paramyotonia congenita uncouple Links et al., 1990) . Unfortunately, most of these reported inactivation from activation. Neuron 1994; 12: 281-94. cases, as shown in reported in hyperkalaemic periodic paralysis, a muscle sodium channel disorder as mentioned above (Bradley et al., 1990) . is underway in probands of this group of 13 families, and other candidate genes will be screened for mutations if no In conclusion, the present study demonstrates that genetic Nat Genet 1994; 6: 267-72. characterization of hypoPP patients is important to decipher the clinical and histopathological features of the disease, and Fouad G, Dalakas M, Servidei S, Mendell JR, Van den Bergh P, to predict the response to therapy. We suggest that mutations Angelini C, et al. Genotype-phenotype correlations of DHP receptor in the SCN4A gene should be systematically sought in hypoPP alpha 1-subunit gene mutations causing hypokalemic periodic patients suffering from paralytic attacks followed by myalgias paralysis. Neuromuscul Disord 1997; 7: 33-8. or worsened by acetazolamide, and when muscle biopsies 
